HomeCompareUNEX vs ABBV

UNEX vs ABBV: Dividend Comparison 2026

UNEX yields 36.30% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UNEX wins by $86.8K in total portfolio value
10 years
UNEX
UNEX
● Live price
36.30%
Share price
$5.51
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$189.1K
Annual income
$29,459.27
Full UNEX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — UNEX vs ABBV

📍 UNEX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUNEXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UNEX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UNEX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UNEX
Annual income on $10K today (after 15% tax)
$3,085.30/yr
After 10yr DRIP, annual income (after tax)
$25,040.38/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, UNEX beats the other by $3,984.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UNEX + ABBV for your $10,000?

UNEX: 50%ABBV: 50%
100% ABBV50/50100% UNEX
Portfolio after 10yr
$145.7K
Annual income
$27,115.51/yr
Blended yield
18.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

UNEX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UNEX buys
0
ABBV buys
0
No recent congressional trades found for UNEX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUNEXABBV
Forward yield36.30%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$189.1K$102.3K
Annual income after 10y$29,459.27$24,771.77
Total dividends collected$138.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: UNEX vs ABBV ($10,000, DRIP)

YearUNEX PortfolioUNEX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,330$3,629.76$11,550$430.00+$2.8KUNEX
2$20,194$4,861.09$13,472$627.96+$6.7KUNEX
3$28,010$6,402.24$15,906$926.08+$12.1KUNEX
4$38,270$8,299.20$19,071$1,382.55+$19.2KUNEX
5$51,546$10,597.36$23,302$2,095.81+$28.2KUNEX
6$68,494$13,339.92$29,150$3,237.93+$39.3KUNEX
7$89,855$16,566.41$37,536$5,121.41+$52.3KUNEX
8$116,456$20,311.13$50,079$8,338.38+$66.4KUNEX
9$149,210$24,601.97$69,753$14,065.80+$79.5KUNEX
10$189,114$29,459.27$102,337$24,771.77+$86.8KUNEX

UNEX vs ABBV: Complete Analysis 2026

UNEXStock

Unex Holdings Inc., a development stage company, intends to provide geodesy services. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Full UNEX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this UNEX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UNEX vs SCHDUNEX vs JEPIUNEX vs OUNEX vs KOUNEX vs MAINUNEX vs JNJUNEX vs MRKUNEX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.